Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6286085rdf:typepubmed:Citationlld:pubmed
pubmed-article:6286085lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6286085lifeskim:mentionsumls-concept:C0027567lld:lifeskim
pubmed-article:6286085lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:6286085lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:6286085lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:6286085lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:6286085lifeskim:mentionsumls-concept:C0024552lld:lifeskim
pubmed-article:6286085pubmed:issue6lld:pubmed
pubmed-article:6286085pubmed:dateCreated1982-10-29lld:pubmed
pubmed-article:6286085pubmed:abstractTextTwenty Malaysian patients with unresectable primary liver cell cancer were prospectively studied at the General Hospital, Kuala Lampur, and were compared for clinical features with an equal number each of African and American patients being studied by the Eastern Cooperative Oncology Group. The patients received intravenous 5-FU and oral MeCCNU which was used for the first time in an Asian country. Most of the Malaysian patients were Chinese, belonged to younger age groups, and presented with massive hepatomegaly, jaundice, and fever. Toxicity to MeCCNU invariably occurred in the form of leukopenia or thrombocytopenia, but none life threatening. Partial response was seen in 20% of Malaysians as compared to 16% in Americans and none in Africans. Malaysians achieved a median survival of 16 weeks compared to 28 weeks in Americans and only eight weeks in Africans. Malaysian Chinese patients were all HBc Ab + ve. Other factors which may have played an etiologic role in the induction of primary liver cancer included alcohol, Chinese herbal medicines, aflatoxin and habitual use of medicated rubbing oils.lld:pubmed
pubmed-article:6286085pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6286085pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6286085pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6286085pubmed:languageenglld:pubmed
pubmed-article:6286085pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6286085pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6286085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6286085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6286085pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6286085pubmed:statusMEDLINElld:pubmed
pubmed-article:6286085pubmed:monthSeplld:pubmed
pubmed-article:6286085pubmed:issn0008-543Xlld:pubmed
pubmed-article:6286085pubmed:authorpubmed-author:FalksonGGlld:pubmed
pubmed-article:6286085pubmed:authorpubmed-author:BalasegaramMMlld:pubmed
pubmed-article:6286085pubmed:authorpubmed-author:CarboneP PPPlld:pubmed
pubmed-article:6286085pubmed:authorpubmed-author:BennettJ MJMlld:pubmed
pubmed-article:6286085pubmed:authorpubmed-author:JoishyS KSKlld:pubmed
pubmed-article:6286085pubmed:authorpubmed-author:MoertelCClld:pubmed
pubmed-article:6286085pubmed:authorpubmed-author:MacIntyreJ...lld:pubmed
pubmed-article:6286085pubmed:issnTypePrintlld:pubmed
pubmed-article:6286085pubmed:day15lld:pubmed
pubmed-article:6286085pubmed:volume50lld:pubmed
pubmed-article:6286085pubmed:ownerNLMlld:pubmed
pubmed-article:6286085pubmed:authorsCompleteYlld:pubmed
pubmed-article:6286085pubmed:pagination1065-9lld:pubmed
pubmed-article:6286085pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:meshHeadingpubmed-meshheading:6286085-...lld:pubmed
pubmed-article:6286085pubmed:year1982lld:pubmed
pubmed-article:6286085pubmed:articleTitleClinical and chemotherapeutic study of hepatocellular carcinoma in Malaysia: a comparison with African and American patients.lld:pubmed
pubmed-article:6286085pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6286085pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:6286085pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed